Intra-tumoural RAMP1+ B cells promote resistance to neoadjuvant anti-PD-1-based therapy in oesophageal squamous cell carcinoma
The study suggests that RAMP1(+) B cells play a critical role in mediating resistance to neoadjuvant immunotherapy in ESCC. Targeting the CGRP-RAMP axis remodels B cells and enhance the efficacy of current immunotherapies, providing new strategies for overcoming treatment resistance.
Authors
- Pingjing Zhou
- Liqun Jiang (ORCID: https://orcid.org/0000-0002-8541-7539)
- Hongyu Zhang (ORCID: https://orcid.org/0000-0002-8078-4401)
- Yuchen Zhang (ORCID: https://orcid.org/0000-0003-4441-0346)
- Jie Gu (ORCID: https://orcid.org/0000-0002-8852-5164)
- Yifan Guo (ORCID: https://orcid.org/0009-0008-9281-6440)
Institutions
- Sun Yat-sen University (CN)
- Fudan University (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- First People's Hospital of Jingzhou (CN)
Publication Details
- Journal
- Immunotherapy Advances
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1093/immadv/ltaf012
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.28